116 related articles for article (PubMed ID: 16709811)
1. Stimulation through CD40 on mouse and human renal cell carcinomas triggers cytokine production, leukocyte recruitment, and antitumor responses that can be independent of host CD40 expression.
Shorts L; Weiss JM; Lee JK; Welniak LA; Subleski J; Back T; Murphy WJ; Wiltrout RH
J Immunol; 2006 Jun; 176(11):6543-52. PubMed ID: 16709811
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells.
Kinoshita Y; Kono T; Yasumoto R; Kishimoto T; Wang CY; Haas GP; Nishisaka N
J Immunother; 2001; 24(3):205-11. PubMed ID: 11394497
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4.
Hillman GG; Younes E; Visscher D; Hamzavi F; Kim S; Lam JS; Montecillo EJ; Ali E; Pontes JE; Puri RK; Haas GP
Clin Cancer Res; 1997 Oct; 3(10):1799-806. PubMed ID: 9815566
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for lung metastases of murine renal cell carcinoma: synergy between radiation and cytokine-producing tumor vaccines.
Nishisaka N; Maini A; Kinoshita Y; Yasumoto R; Kishimoto T; Jones RF; Morse P; Hillman GG; Wang CY; Haas GP
J Immunother; 1999 Jul; 22(4):308-14. PubMed ID: 10404432
[TBL] [Abstract][Full Text] [Related]
5. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
[TBL] [Abstract][Full Text] [Related]
6. OX40 ligand-transduced tumor cell vaccine synergizes with GM-CSF and requires CD40-Apc signaling to boost the host T cell antitumor response.
Gri G; Gallo E; Di Carlo E; Musiani P; Colombo MP
J Immunol; 2003 Jan; 170(1):99-106. PubMed ID: 12496388
[TBL] [Abstract][Full Text] [Related]
7. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
8. Combination of radiation and vaccination with autologous tumor cells expressing IL-2, IFN-gamma and GM-CSF for treatment of murine renal carcinoma.
Maini A; Nishisaka N; Kinoshita Y; Jones RF; Wang CY; Haas GP
In Vivo; 2003; 17(2):119-23. PubMed ID: 12792971
[TBL] [Abstract][Full Text] [Related]
9. CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors.
Rakhmilevich AL; Buhtoiarov IN; Malkovsky M; Sondel PM
Cancer Immunol Immunother; 2008 Aug; 57(8):1151-60. PubMed ID: 18214476
[TBL] [Abstract][Full Text] [Related]
10. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor.
Tannenbaum CS; Tubbs R; Armstrong D; Finke JH; Bukowski RM; Hamilton TA
J Immunol; 1998 Jul; 161(2):927-32. PubMed ID: 9670971
[TBL] [Abstract][Full Text] [Related]
11. Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses.
Murphy WJ; Welniak L; Back T; Hixon J; Subleski J; Seki N; Wigginton JM; Wilson SE; Blazar BR; Malyguine AM; Sayers TJ; Wiltrout RH
J Immunol; 2003 Mar; 170(5):2727-33. PubMed ID: 12594303
[TBL] [Abstract][Full Text] [Related]
12. CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis.
Pan J; Burdick MD; Belperio JA; Xue YY; Gerard C; Sharma S; Dubinett SM; Strieter RM
J Immunol; 2006 Feb; 176(3):1456-64. PubMed ID: 16424173
[TBL] [Abstract][Full Text] [Related]
13. In vivo and in vitro regulation of type I IFN synthesis by synergistic effects of CD40 and type II IFN.
Greene JA; DeVecchio JL; Gould MP; Auletta JJ; Heinzel FP
J Immunol; 2006 May; 176(10):5995-6003. PubMed ID: 16670308
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells.
Turner JG; Rakhmilevich AL; Burdelya L; Neal Z; Imboden M; Sondel PM; Yu H
J Immunol; 2001 Jan; 166(1):89-94. PubMed ID: 11123280
[TBL] [Abstract][Full Text] [Related]
15. Critical role for IL-4 in the development of transplant arteriosclerosis in the absence of CD40-CD154 costimulation.
Ensminger SM; Spriewald BM; Sorensen HV; Witzke O; Flashman EG; Bushell A; Morris PJ; Rose ML; Rahemtulla A; Wood KJ
J Immunol; 2001 Jul; 167(1):532-41. PubMed ID: 11418692
[TBL] [Abstract][Full Text] [Related]
16. Growth and major histocompatibility antigen expression regulation by IL-4, interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha) on human renal cell carcinoma.
Hillman GG; Puri RK; Kukuruga MA; Pontes JE; Haas GP
Clin Exp Immunol; 1994 Jun; 96(3):476-83. PubMed ID: 8004818
[TBL] [Abstract][Full Text] [Related]
17. IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy.
Berner V; Liu H; Zhou Q; Alderson KL; Sun K; Weiss JM; Back TC; Longo DL; Blazar BR; Wiltrout RH; Welniak LA; Redelman D; Murphy WJ
Nat Med; 2007 Mar; 13(3):354-60. PubMed ID: 17334371
[TBL] [Abstract][Full Text] [Related]
18. Role of GM-CSF signaling in cell-based tumor immunization.
Zarei S; Schwenter F; Luy P; Aurrand-Lions M; Morel P; Kopf M; Dranoff G; Mach N
Blood; 2009 Jun; 113(26):6658-68. PubMed ID: 19282460
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of a dual cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM expressing tumor cells.
Schanzer JM; Fichtner I; Baeuerle PA; Kufer P
J Immunother; 2006; 29(5):477-88. PubMed ID: 16971804
[TBL] [Abstract][Full Text] [Related]
20. Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma.
Doehn C; Esser N; Pauels HG; Kiessig ST; Stelljes M; Grossmann A; Jocham D; Drevs J
Eur Urol; 2009 Jul; 56(1):123-31. PubMed ID: 18550267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
